Ta‐Kai Li

发表

Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP

W. Novotny, Y. Ou, S. Sahasranaman, 2020, British journal of clinical pharmacology.

Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2

B. Bartosch, J. Dubuisson, F. Cosset, 2005, Journal of Virology.

Calcium‐ and FK506‐independent interaction between the immunophilin FKBP51 and calcineurin *

S. Baksh, B. Bierer, A. Cristillo, 2002 .

Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.

A. Tarr, J. Ball, J. Witteveldt, 2008, The Journal of general virology.

Definition of a Conserved Immunodominant Domain on Hepatitis C Virus E2 Glycoprotein by Neutralizing Human Monoclonal Antibodies

S. Lemon, Arvind H. Patel, J. Ball, 2008, Journal of Virology.

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects

W. Novotny, S. Mu, Y. Ou, 2019, Cancer Chemotherapy and Pharmacology.

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

W. Novotny, R. Preston, T. Marbury, 2020, Leukemia & lymphoma.

Hepatitis C Virus E2 Has Three Immunogenic Domains Containing Conformational Epitopes with Distinct Properties and Biological Functions

J. Dubuisson, Z. Keck, S. Foung, 2004, Journal of Virology.

Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV Virions

Z. Keck, S. Foung, A. Owsianka, 2006, Journal of Virology.